Physician profile
Larry Charleston
NPI 1730314782
$283,753.05
in general payments reported to CMS, 2019-2025
23 companies · $76K in 2025
The $76K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622 · 2020: $22K · 2021: $48K · 2022: $35K · 2023: $42K · 2024: $60K · 2025: $76K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $88K · Honoraria: $39K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Travel and Lodging: $20K · Food and Beverage: $8,752 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $88,456.80 |
| Honoraria | $39,013.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,837.00 |
| Travel and Lodging | $20,023.34 |
| Food and Beverage | $8,752.32 |
| Education | $122.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $82,330.17 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Pfizer INC. | $66,810.28 | 2023-2025 | |
| Allergan, INC. | $39,437.14 | 2019-2022 | |
| Axsome Therapeutics, INC. | $38,241.02 | 2025 | Symbravo |
| Teva Pharmaceuticals USA, INC. | $19,300.15 | 2019-2025 | Ajovy |
| Amneal Pharmaceuticals LLC | $13,062.00 | 2021-2025 | Brekiya, Zomig |
| Amgen INC. | $10,672.87 | 2021-2023 | Aimovig |
| Lundbeck LLC | $10,112.04 | 2020-2025 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $2,940.00 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $204.80 | 2022 | |
| Lilly USA, LLC | $129.12 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.67 | 2022-2023 | Gammagard Liquid |
| Argenx US, INC. | $85.13 | 2023-2025 | Vyvgart Hytrulo |
| Impel Pharmaceuticals INC. | $82.99 | 2022 | |
| Tg Therapeutics, INC. | $48.60 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $41.50 | 2024 | Qutenza |
| Eli Lilly and Company | $40.53 | 2024 | |
| Ucb, INC. | $25.08 | 2025 | Fintepla |
| Novo Nordisk INC | $24.24 | 2023 | |
| Boston Scientific Corporation | $18.94 | 2024 | |
| Alexion Pharmaceuticals, INC. | $18.63 | 2023 | Koselugo |
| Genentech USA, INC. | $18.29 | 2024 | Enspryng, Ocrevus |
| Neurocrine Biosciences, INC. | $14.86 | 2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Charleston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.